This Analyst Still Has Confidence In Atai Life Sciences’ Pipeline Despite Recent Setbacks
HC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ:ATAI) from $50 to $20 to reflect recent adverse outcomes in programs…
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood’s Latest Moves And More
Psychedelics Take Center Stage In Davos
Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Cathie Wood Reacts To Atai’s Drastic Stock Plunge After Doomed Clinical Study Results
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche
Citigroup Maintains Buy on ATAI Life Sciences, Lowers Price Target to $10
Citigroup analyst Neena Bitritto-Garg maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and lowers the price target from $20 to $10.
atai Life Sciences Company GABA Therapeutics Announces Final Results From Phase 1 Single And Multiple Ascending Dose Trial Of GRX-917
GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as
atai Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.).
Dow Jumps 700 Points; S&P 500 Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.
EF Hutton Maintains Buy on ATAI Life Sciences, Lowers Price Target to $15
EF Hutton analyst Elemer Piros maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and lowers the price target from $23 to $15.
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.
Atai Life Sciences’ Depression Candidate Faces Trial Setback, Shares Nosedive
Atai Life Sciences (NASDAQ:ATAI)-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a…